Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid, small caps lead the gainers
Tue, 2 Sep 01:30 pm

Indian stock market continued its sustained northward journey led by continuous buying among the index heavyweights. The mid and small cap stocks lead the index gainers. Among the sectoral indices, barring metals, all sectoral indices are trading higher. Healthcare and realty sector stocks are leading the pack of gainers.

The BSE-Sensex is trading up 150 points. The NSE-Nifty is trading up 51 points. The BSE Mid Cap index is trading up 1.1% and the BSE Small Cap index is trading up 1.2%. The rupee is trading at 60.47 to the US dollar.

Auto stocks are trading mixed today. While TVS Motors is trading higher, Tata Motors is trading in the red. As per a leading business daily, Bajaj Auto reported its sales volume data for the month of August 2014. The two wheelers maker's total sales volume increased to 3.36 lakh units in the month, which was up by 8% YoY as compared to the same month the last year. Its motorcycle sales grew marginally by 2% YoY in August 2014. At 2.8 lakh units, the company's motorcycle volumes comprise over 80% of total sales volumes. Majority of the growth was witnessed in the commercial vehicles sales that grew by 56% YoY in the month to 52,538 units. Sales of exports increased by 21% YoY to 175,127 units. The company management expects it sales volumes to cross 4 lakhs unit mark in the current month. The stock of Bajaj Auto is trading higher by 1% today.

Almost all Indian Pharma stocks are trading on a positive note today. Cipla is leading the pack of gainers, however Wockhardat is trading lower. As per a leading business daily, Cipla has launched an anti-asthma inhaler in the European countries of Germany and Sweden. Cipla's asthma drug is a generic version of GlaxoSmithKline Plc's top selling product Advair. Advair is GSK's US$ 8 bn dollar product. Last December, Denmark became the first European country to approve marketing of GSK's Advair. Cipla's launch of generic version of Advair will dent latter's sales in the European countries. Cipla will market the drug under the name Serrofloin in Germany and Salmeterol or Fluticasone Cipla in Sweden.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid, small caps lead the gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.